18:16 , Sep 28, 2018 |  BioCentury  |  Finance

Morphic reloads

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace. Existing investor Omega Funds and new investor Novo Holdings A/S...
13:56 , Sep 25, 2018 |  BC Extra  |  Financial News

Morphic's $80M round paves way for integrin clinical studies

Morphic Therapeutic (Waltham, Mass.) raised $80 million in a series B round led by existing investor Omega Funds and new investor Novo Holdings A/S (Hellerup, Denmark). New investors Invus and EcoR1 Capital, and existing investors...
03:14 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

New Phase IIb analyses support further development of Protagonist's UC candidate

Protagonist Therapeutics Inc. (NASDAQ:PTGX) said new analyses from the discontinued Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis showed that the initial findings by an IDMC were "an unfortunate consequence...
17:00 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Takeda's subcutaneous Entyvio meets in Phase III for maintenance therapy of ulcerative colitis

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said subcutaneous Entyvio vedolizumab as maintenance therapy met the primary endpoint vs. placebo in the Phase III VISIBLE 1 trial to treat ulcerative colitis in patients who achieved a clinical...
23:16 , Jul 20, 2018 |  BC Extra  |  Preclinical News

PI3K inhibitors may block cancer's access to CNS

Researchers from Duke University, Gilead Sciences Inc. (NASDAQ:GILD) and colleagues suggested that acute lymphoblastic leukemia (ALL) cells metastasize to the CNS by traveling along vessels rich in laminin, a protein associated with motility of neuronal...
16:35 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million on July 16 in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures,...
17:45 , Jul 18, 2018 |  BioCentury  |  Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday, joined...
17:33 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermal ulcers Mouse studies suggest a laminin peptide-antioxidant conjugate could help treat diabetic foot ulcers. The conjugate consists of a 12-mer peptide derived from LAMA5, which interacts with CD49C/CD29 and other integrins to promote...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis as...
17:56 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...